A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis

被引：0
作者：
Ahmadreza Jamshidi
Farhad Gharibdoost
Mahdi Vojdanian
Soosan G. Soroosh
Mohsen Soroush
Arman Ahmadzadeh
Mohammad Ali Nazarinia
Mohammad Mousavi
Hadi Karimzadeh
Mohammad Reza Shakibi
Zahra Rezaieyazdi
Maryam Sahebari
Asghar Hajiabbasi
Ali Asghar Ebrahimi
Najmeh Mahjourian
Amin Mohammadinejad Rashti
机构：
[1] Rheumatology Research Center,Department of Rheumatology
[2] Tehran University of Medical Sciences,Department of Rheumatology
[3] AJA university of Medical Sciences Rheumatology research center,Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences
[4] AJA university of Medical Sciences Internal medicine,Rheumatic Diseases Research Center, Faculty of Medicine
[5] Rheumatology Section,Guilan Rheumatology Research Center, Department of Rheumatology, Razi Hospital, School of Medicine
[6] Loghman e Hakim Hospital,undefined
[7] Shahid Beheshti University of Medical Sciences,undefined
[8] Shiraz Geriatric Research Center,undefined
[9] Shiraz University of Medical Sciences,undefined
[10] Department of Rheumatology,undefined
[11] School of Medicine,undefined
[12] Shahrekord University of Medical Sciences,undefined
[13] Shahrekord AND Behcet’s Unit,undefined
[14] Rheumatology Research Center,undefined
[15] Tehran University of Medical Sciences,undefined
[16] Al-Zahra Hospital,undefined
[17] Kerman University of Medical Sciences,undefined
[18] Mashhad University of medical Sciences,undefined
[19] Guilan University of Medical Sciences,undefined
[20] Tabriz University of Medical Sciences,undefined
[21] Connective Tissue Reserch Center,undefined
[22] Tehran University of Medical Sciences,undefined
[23] Tehran University of Medical Sciences,undefined
[24] Faculty of Pharmacy,undefined
来源：
Arthritis Research & Therapy | / 19卷
关键词：
Adalimumab; Biosimilar; CinnoRA®; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 117 条
  • [1] McInnes IB(2007)Cytokines in the pathogenesis of rheumatoid arthritis Nat Rev Immunol 7 429-42
  • [2] Schett G(2000)Pharmacoeconomics of drug therapy for rheumatoid arthritis Rheumatology (Oxford) 39 43-7
  • [3] Tugwell P(2001)Rheumatoid arthritis Lancet 358 903-12
  • [4] Lee DM(2004)Epidemiology and burden of illness of rheumatoid arthritis Pharmacoeconomics 22 1-86
  • [5] Weinblatt ME(2011)American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials Arthritis Rheum 63 573-74
  • [6] Kvien TK(2012)2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis Rev Bras Reumatol 52 152-75
  • [7] Felson DT(2010)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs Ann Rheum Dis 69 964-39
  • [8] Smolen JS(2012)2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Arthritis Care Res 64 625-38
  • [9] Wells G(2013)Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study Arthritis Rheum 65 28-8
  • [10] Zhang B(1998)A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis Rheumatology 37 1060-16
12345678910